Galectin Therapeutics (GALT) Cash & Equivalents (2010 - 2026)

Galectin Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $14.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 89.89% year-over-year to $14.1 million; the TTM figure through Mar 2026 stood at $14.1 million (up 89.89% YoY), while the FY2025 annual figure was $17.7 million, up 17.2% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $14.1 million, down from $17.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $31.6 million in Q1 2022, with the low at $7.4 million in Q1 2025.
• The 5-year median for Cash & Equivalents is $18.0 million (2023), against an average of $19.3 million.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents tumbled 68.45% in 2025, then jumped 89.89% in 2026.
• Galectin Therapeutics' Cash & Equivalents stood at $18.6 million in 2022, then surged by 38.02% to $25.7 million in 2023, then slumped by 41.08% to $15.1 million in 2024, then increased by 17.2% to $17.7 million in 2025, then fell by 20.37% to $14.1 million in 2026.
• Business Quant data shows GALT's Cash & Equivalents at $14.1 million in Q1 2026, $17.7 million in Q4 2025, and $11.5 million in Q3 2025.